ラパリズム錠1mg e-learning

関連文献リスト

患者向け資材

学会・講演会情報

nobel_park_logo

メドピア

カスタマーセンター

トピックス

  1. ホーム > 
  2. トピックス
A35 | I'VE GOT A FEELING WE'RE GOING TO SOLVE THIS ONE:
INSIGHTS INTO LYMPHANGIOLEIOMYOMATOSIS

Facilitators: J.M. D'Armiento, MD, PhD, S.Y. El-Chemaly, MD, MPH, D.F. Dilling, MD, L.R. Young, MD

Session Info: Thematic Poster Session, [A35] I'VE GOT A FEELING WE'RE GOING TO SOLVE THIS ONE: INSIGHTS
INTO LYMPHANGIOLEIOMYOMATOSIS

Day/Date: Sunday, May 17, 2015

Session Time: 9:30 AM - 4:15 PM

Poster Viewing: 11:30-1:15

Room: Area G, Hall A-B (Upper Level)

Location: Colorado Convention Center

[Poster Board # P758] Eighteen Months Sirolimus Medication Benefits not Only Patients with Moderate to Severe LAM but also Those with Mild Disease, [Publication Number: A1393]

K. Nakata, MD, PhD1, Y. Inoue, MD, PhD2, K. Seyama, MD, PhD3, R. Tazawa, MD, PhD1, T. Tamada, MD, PhD4, M.

Suzuki, MD PhD5, M. Mishima, MD, PhD6, A. Mikami, MD7

1Niigata/JP, 2Osaka/JP, 38421/JP, 48574/JP, 58648/JP, 68567/JP, 71193/JP

MLSTS group in Japan

Multicenter international lymphangioleiomyomatosis efficacy of Sirolimus (MILES) trial conducted during 2006 to 2010

in US, Japan, and Canada revealed that sirolimus stabilized lung function, reduced symptoms, and improved QOL. In

this trial, 28 Japanese patients with LAM were enrolled and 24 completed the two-year trial course. PMDA (Japanese

FDA) demanded us to perform an open labeled single arm trial on more than 50 Japanese patients for confirmation of

safety, because only 13 Japanese patients had been assigned to Sirolimus group in MILES trial. The new trial,

multicenter lymphangioleiomyomatosis Sirolimus trial for safety (MLSTS) had been conducted during September 2012

to March 2015, in which 55 patients has been treated with 2 mg daily for 18 months as a single arm open-labeled

multicenter clinical trial. Distinct from MILES trial, patients with mild disease (present FEV1>70%, n=24) were not

excluded from enrollment, and thus, the new trial might assess the efficacy of early intervention for longer treatment

period. At 18 months treatment, the mean increase in FEV1 was 75 ml compared with the baseline data (n=44). Of

those 24 patients with %FEV1 less than 70%, the increase was 61ml, whereas it rather decreased by 6 months and

then increased by 18 months with 93ml in 20 patients with %FEV1 more than 70%. Using Friedman test, it was found

that FEV1 was not significantly smaller than the baseline level at 3, 6, 9,12, and 18 months in both patients with

%FEV1 >70% (mild) and <70% (moderate to severe). Similarly, the mean increase in FVC for 18 months treatment

was 38ml for all 44 patients tested, and the increases were 52 and 27 ml for patients with mild and moderate/severe

disease, respectively. There was no significant reduction in FVC during 18 month in both patient groups. One thousand

two hundred eighty six adverse events were reported in 18 months. Of those, 27 were severe adverse events with 3

cases of mild sirolimus pneumonitis that resolved within one month after cessation of sirolimus medication. There was

no difference in the frequency of adverse events between two groups. Thus, MLSTS data suggested that early

intervention by long-term sirolimus medication might inhibit the progression of LAM.

Months

ページのトップへ

サイトマップ    個人情報保護方針    著作権について    ご利用にあたって

© 2017.Nobelpharma Co., Ltd. all right reserved.